OBJECTIVES

Primary Objective: To evaluate the effectiveness of HCV genotype 1 treatment with LDV/SOF, as measured by SVR12 in the Massachusetts Medicaid program.

Secondary Objectives: To evaluate the effectiveness of HCV genotype 1 treatment with LDV/SOF within the subgroups of 8, 12, and 24-week regimens, and to identify predictors of treatment failure

METHODS

This retrospective cohort study utilized clinical and demographic data that is routinely compiled from PA requests for the comprehensive HCV medication management program of the Massachusetts Medicaid program in an internal database, as well as pharmacy claims data from the MassHealth PFS.

Inclusion Criteria:
- Member is over 18 years of age
- Diagnosis of HCV genotype 1
- Completion of at least one 8-week, 12-week, or 24-week course of LDV/SOF with or without ribavirin between October 10, 2014 and November 1, 2016
- Availability of SVR12 result or detectable viral load any time after treatment completion prior to November 1, 2016

Exclusion Criteria:
- Mixed HCV genotype
- HCV genotype other than genotype 1

Study Variables:
- Vital load data was collected from the internal database of the comprehensive HCV medication management program.
- Other clinical variables included HCV co-infection, SUD, cirrhosis, history of failure on a previous HCV treatment, history of failure on a previous FDA-approved direct-acting antiviral regimen, and presence of portal hypertension.

Statistical Analysis:
- Primary Objective: Vital load data was used to calculate the proportion of all members who completed at least one 8-week, 12-week, or 24-week course of LDV/SOF and achieved SVR12.

- Secondary Objectives: Vital load data was used to calculate the proportion of members who achieved SVR12 by treatment regimen and by clinical and demographic variables for each treatment regimen.

- The number of members with and without each clinical and demographic variable who achieved SVR12 and who did not achieve SVR12 were used to perform bivariate and multivariate analyses and calculate the odds of failure to achieve SVR12.